Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

aTYR PHARMA (ATYR) EPS (Basic) (2019 - 2025)

Historic EPS (Basic) for aTYR PHARMA (ATYR) over the last 6 years, with Q3 2025 value amounting to -$0.26.

  • aTYR PHARMA's EPS (Basic) fell 1304.35% to -$0.26 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.82, marking a year-over-year increase of 1276.6%. This contributed to the annual value of -$0.91 for FY2024, which is 270.98% up from last year.
  • As of Q3 2025, aTYR PHARMA's EPS (Basic) stood at -$0.26, which was down 1304.35% from -$0.22 recorded in Q2 2025.
  • In the past 5 years, aTYR PHARMA's EPS (Basic) ranged from a high of -$0.17 in Q1 2025 and a low of -$0.46 during Q3 2022
  • In the last 4 years, aTYR PHARMA's EPS (Basic) had a median value of -$0.23 in 2024 and averaged -$0.26.
  • Per our database at Business Quant, aTYR PHARMA's EPS (Basic) soared by 5652.17% in 2023 and then tumbled by 1500.0% in 2024.
  • Over the past 4 years, aTYR PHARMA's EPS (Basic) (Quarter) stood at -$0.26 in 2022, then increased by 3.85% to -$0.25 in 2023, then increased by 14.79% to -$0.21 in 2024, then dropped by 22.05% to -$0.26 in 2025.
  • Its EPS (Basic) was -$0.26 in Q3 2025, compared to -$0.22 in Q2 2025 and -$0.17 in Q1 2025.